Atopic Dermatitis News

• Expert Highlights Biologics in the Pipeline for Eczema Dr David Rosmarin reviewed several biologics in clinical trials that target interleukin-4 and other receptors.
  MDedge News, January 05, 2024
• Assessing Patients With AD: Tools to Use in the Office "It can be overwhelming because there are many choices but so little time," says Dr Jonathan Silverberg, of George Washington University, Washington, DC.
  MDedge News, January 04, 2024
• Experimental Topical Drug Shows Promise for AD, Psoriasis In the phase 2 study, researchers at 34 sites in four countries randomized 104 patients with mild to moderate AD or psoriasis to receive the topical PDE4 inhibitor or a vehicle once daily for 6 weeks.
  MDedge News, January 04, 2024
• 5-Year Safety Data From Upadacitinib Trials Reported Upadacitinib trials in atopic dermatitis have included diverse patient groups with varying risk factors, according to Dr Christopher Bunick.
  MDedge News, January 03, 2024
• Conjunctivitis: How Common Is It in Patients on Dupilumab? Adults with AD have a significant and disease severity–dependent increased risk of developing ocular surface diseases, including conjunctivitis and keratitis.
  MDedge News, December 29, 2023
• Long COVID: New Info on Who Is Most Likely to Get It Fresh research and clinical anecdotes have given experts a much clearer picture of which patients are most likely to develop long COVID.
  Medscape Medical News, December 27, 2023
• Keeping Injectable Products in Cosmetic Dermatology Safe The rapid increase in intradermal injections of hyaluronic acid and Botox has been accompanied by an increase in side effects.
  Medscape Medical News, December 26, 2023
• Paradoxical Eczema Risk Low With Biologic Psoriasis Tx Ali Al-Janabi, MA, and associates found that 273 (1%) of approximately 25,000 drug exposures in 13,699 biologic-treated patients with psoriasis were associated with paradoxical eczema.
  MDedge News, December 22, 2023
• How Does Lebrikizumab Perform Across Different Subgroups? Key eligibility criteria for both trials included adults or adolescents with a diagnosis of AD as defined by the AAD consensus criteria, for at least 1 year prior to screening.
  MDedge News, December 18, 2023
• Alert FDA Approves Tralokinumab for Treating Eczema in Adolescents It is the first treatment for pediatric patients with moderate-to-severe atopic dermatitis that specifically targets the interleukin (IL)-13 cytokine.
  Medscape Medical News, December 15, 2023
• Disease Control Elusive for Many Patients on AD Therapies A significant number of patients with moderate to severe atopic dermatitis (AD) failed to achieve adequate disease control with systemic therapies over 12 months, indicating a substantial degree of "therapeutic inertia."
  MDedge News, December 14, 2023
• Tape Strips Detect Hidradenitis Suppurativa Biomarkers "Tape strips can provide important clues to when and which drugs to use in HS in patients with both early and late disease, which can change clinical practice."
  MDedge News, December 08, 2023
• Patients With hEDS Report Skin Laxity, Scarring Follicular occlusion, mast cell disease, and eczema were common presentations among patients with hypermobile Ehlers-Danlos syndrome.
  MDedge News, December 07, 2023
• Hope Emerges for Patients With Rare Skin Disorder "A new framework for thinking about and treating these diseases is emerging."
  Medscape Medical News, December 05, 2023
• MSWS 2023 Misdiagnoses Among Challenges in Managing Cutaneous Lymphoma Although predictive tools to identify those at risk of disease progression are in their infancy, the development of such tools is crucial for improving patient outcomes.
  Medscape Medical News, December 02, 2023
• EADV 2023 Novel Subcutaneous Biologics Show Promise in AD Patients with moderate to severe atopic dermatitis could soon have more therapeutic options, with monoclonal antibodies targeting novel immune pathways that reduce disease severity, suggest two trials.
  Medscape Medical News, December 01, 2023
• Tapinarof Effective for AD in Patients as Young as 2 years Tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, was approved in 2022 for treating plaque psoriasis in adults.
  MDedge News, November 28, 2023
• Parent Concerns a Factor When Treating Patients With AD For a parent whose child has an inflammatory skin disease, pigmentation changes, rather than inflammation, might be the reason that he or she brought the child to the clinician.
  MDedge News, November 23, 2023
• Lebrikizumab Gets the Nod in the EU for Atopic Dermatitis Lebrikizumab, an interleukin-13 inhibitor, is not yet approved in the United States.
  MDedge News, November 20, 2023
• EADV 2023 Topical Ivermectin Study Sheds Light on Dysbiosis in Rosacea Study findings show that ivermectin reduces the density of Demodex folliculorum in rosacea lesions, but the skin microbiome takes time to recover.
  Medscape Medical News, November 03, 2023
• CV, VTE Risk Not Seen in Derm Studies of JAK Inhibitors "There remains a knowledge gap regarding the risk of JAK inhibitor use and VTE and/or MACE in the dermatologic population," the study authors wrote.
  MDedge News, November 01, 2023
• EADV 2023 Study Finds Ruxolitinib Effective, Safe for Children With AD There were no significant safety signals in the younger pediatric population, and 'no treatment-emergent adverse events suggestive of systemic JAK inhibition,' Dr Lawrence Eichenfield said.
  MDedge News, November 01, 2023
• Dupilumab-Associated Lymphoid Reactions Require Caution Retrospective study identifies potential for misdiagnosed mycosis fungoides and for dupilumab to fuel cutaneous lymphoid reactions that mimic mycosis fungoides in patients with atopic dermatitis.
  Medscape Medical News, October 30, 2023
• EADV 2023 Nemolizumab Promise for Prurigo Nodularis Continues Results from OLYMPIA 1 provide further support for nemolizumab as a potential first-in-class prurigo nodularis treatment; in another study, a JAK inhibitor was beneficial in patients with PN.
  Medscape Medical News, October 25, 2023
• GW Teledermatology Model Expands to Four Underserved Areas Four institutions will receive grants to implement the model, which involved partnering with a local organization to provide an entry point for individuals in areas with limited access to medical care.
  MDedge News, October 25, 2023
• Bullying More Prevalent Among Adolescents With AD Data were collected from adult caregivers of more than 3200 adolescents in the United States.
  Medscape Medical News, October 25, 2023
• EADV 2023 Recombinant IL-2 Shows Potential in Atopic Dermatitis "This is the first study to demonstrate the therapeutic potential of rezpegaldesleukin," said Jonathan Silverberg, MD, PhD, MPH, who presented results of a phase 1b study.
  Medscape Medical News, October 18, 2023
• Lilly's Bowel Disease Drug Succeeds in Late-Stage Study Eli Lilly has said its experimental drug met the main goals of a late-stage study to test it as a treatment for moderately to severely active Crohn's disease.
  Reuters Health Information, October 12, 2023
• FDA Issues Letter Regarding Lebrikizumab Review for AD The FDA has issued a complete response letter regarding lebrikizumab, an investigational biologic for the treatment of adult and adolescent patients with moderate to severe atopic dermatitis.
  MDedge News, October 02, 2023
• Study Finds IBD Risk Higher in Children, Adults with AD Children and adults with atopic dermatitis may be at increased risk for inflammatory bowel disease, researchers report.
  Medscape Medical News, September 28, 2023
• CHMP Recommends Marketing of Biologic for Atopic Dermatitis Lebrikizumab is a monoclonal antibody that binds to cytokine IL-13, which has been implicated in driving the type-2 inflammatory loop in the skin, leading to skin barrier dysfunction.
  MDedge News, September 15, 2023
• Company Submits Supplemental NDA for Topical AD Treatment Submission is based on positive results from two phase 3, vehicle-controlled trials in patients ages 6 and older with mild to moderate AD.
  MDedge News, September 12, 2023
• Tralokinumab Safe, Effective in Older Pop With AD: Analysis The findings are important for the older patient population who "typically face unique treatment challenges," the authors write.
  Medscape Medical News, August 31, 2023
• AD May Be a Risk Factor for GBS Colonization in Pregnancy "The rate of GBS colonization among pregnant females with a history of AD has not been previously reported," the authors of the study wrote.
  Medscape Medical News, August 25, 2023